Also listed on Inozyme Pharma, Inc., an earlier holder on the record. The recorded assignments below show how it moved.
Collateral for a security interest recorded Apr 27, 2026 (Citibank, N.A.).
Term ends Dec 18, 2035 · Low confidence
20-year base term ends Dec 18, 2035
Reissue of US 10,493,135, which was surrendered when this reissue was granted; its term and maintenance fees continue here.
Held by Biomarin Pharmaceutical Inc.
Filed Dec 3, 2020 as application 17/111,156 · Granted May 16, 2023
Base term, 20 years from filing
Today
2015
2035
Clock starts
Dec 18, 2015
Dec 18, 2015
Term ends
Dec 18, 2035
Dec 18, 2035
Granted
May 16, 2023
May 16, 2023
base term
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from the original patent's grant (Dec 3, 2019). This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 0 of 3 maintenance fees are paid so far. Confidence: Low. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 18, 2015, when application PCT/US2015/066646, the earliest non-provisional in its chain, was filed (this one was filed Dec 3, 2020); a parent in its chain could not be resolved (the next row) | Dec 18, 2035 | High confidence |
| Continuity chain | A reissue: its term follows the original patent's, with the original's term adjustment; a parent in the chain could not be resolved | dated from this application's own claim | Low confidence |
| Patent term adjustment | No term adjustment record on a grant after 2005, so none is added | no change | Medium confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | The reissue's fees post to its original, whose fee record is not available (likely before 2001) | In force | Medium confidence |
| Computed term end | The steps above, in order | Dec 18, 2035 | Low confidence |
This family
| Application PCT/US2015/066646 | PCT application no patent term | no patent term |
| US 10,493,135 | Surrendered on reissue May 2023 | May 2023 |
| US RE49,529 | this patent Dec 2035 | Dec 2035 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Nov 25, 2025 Reel 73707, frame 488 | Inozyme Pharma, Inc. | Biomarin Pharmaceutical Inc. | Assignment of Assignor's Interest |
| Apr 27, 2026 Reel 75493, frame 968 | Biomarin Pharmaceutical Inc.; Amicus Therapeutics, Inc. | Citibank, N.A., as Collateral Agent | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Dec 2035
Term ends Dec 18, 2035. Maintenance fees still fall due before then
Citations
0
later US patents cite this one
That is below the median of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.